 WATERTOWN, Mass., Nov. 05, 2020 GLOBE NEWSWIRE -- Selecta Biosciences, Inc. NASDAQ: SELB, a biotechnology company leveraging its clinically validated ImmTORTM platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced financial results for the third quarter ended September 30, 2020 and provided corporate updates. 